Filter:
Able AI
What's the best dilution for CYP2C19 in ?
Tested Applications
| Positive IHC detected in | human liver cancer tissue Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0 |
| Positive IF/ICC detected in | HeLa cells |
Recommended dilution
| Application | Dilution |
|---|---|
| Immunohistochemistry (IHC) | IHC : 1:50-1:500 |
| Immunofluorescence (IF)/ICC | IF/ICC : 1:50-1:500 |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
Product Information
55453-1-AP targets CYP2C19 in IHC, IF/ICC, ELISA applications and shows reactivity with human samples.
| Tested Reactivity | human |
| Host / Isotype | Rabbit / IgG |
| Class | Polyclonal |
| Type | Antibody |
| Immunogen |
Peptide Predict reactive species |
| Full Name | cytochrome P450, family 2, subfamily C, polypeptide 19 |
| Calculated Molecular Weight | 56 kDa |
| GenBank Accession Number | NM_000769 |
| Gene Symbol | CYP2C19 |
| Gene ID (NCBI) | 1557 |
| RRID | AB_2881340 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Antigen affinity purification |
| UNIPROT ID | P33261 |
| Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol, pH 7.3. |
| Storage Conditions | Store at -20°C. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA. |
Protocols
| Product Specific Protocols | |
|---|---|
| IF protocol for CYP2C19 antibody 55453-1-AP | Download protocol |
| IHC protocol for CYP2C19 antibody 55453-1-AP | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
Publications
What published studies show
The CYP2C19 Polyclonal antibody (Cat# 55453-1-AP) has 1 citation. It was cited in FASEB Journal in a 2026 study by Kejun Liu et al., titled "Integrative Multi-Omics Analysis Elucidates the Progressive Disease Landscape and Reveals Dynamic Protein Biomarkers for MASLD Surveillance." The research field is metabolic dysfunction-associated steatotic liver disease (MASLD), focusing on multi-omics analysis and protein biomarker discovery for disease surveillance.
| Species | Application | Title |
|---|---|---|
FASEB J Integrative Multi-Omics Analysis Elucidates the Progressive Disease Landscape and Reveals Dynamic Protein Biomarkers for MASLD Surveillance. |
